EGFR and non-small cell lung carcinoma: Of note, dual targeting CD44/EGFR by HA-based nanoparticles along with systemic administration of plasmid DNA expressing wild-type (wt-) p53 and microRNA-125b (miR-125b) in a genetically engineered mouse model of lung cancer led to an increase of wild-type p53 and miR-125b gene up to 20-fold associated with elevated caspase-3 and APAF-1 expression-induced apoptosis; thus it may represent an effective gene therapy for NSCLC (138).